3-Aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Drug Discovery

Background:

• Tuberculosis (TB) remains a significant global health challenge, necessitating the development of novel therapeutic agents.
• Existing treatments face challenges due to drug resistance and side effects, highlighting the need for new drug candidates.

Purpose of the Study:

• To synthesize and evaluate a library of 3-aryl-substituted imidazo[1,2-a]pyridines as potential antituberculosis agents.
• To identify a lead compound with potent activity against Mycobacterium tuberculosis.

Main Methods:

• Synthesis of 3-aryl-substituted imidazo[1,2-a]pyridines via direct arylation, nitro reduction, and palladium-catalyzed C-N coupling.
• Antitubercular activity screening against Mycobacterium tuberculosis H37Rv.
• Molecular docking studies to elucidate the binding mechanism.

Main Results:

• A library of novel 3-aryl-substituted imidazo[1,2-a]pyridines was successfully synthesized.
• Compound 26 emerged as a potent antituberculosis lead, exhibiting a minimum inhibitory concentration (MIC) of 2.3 μg/ml against M. tuberculosis H37Rv.
• Compound 26 demonstrated a selectivity index of 35 and showed key π-π interactions with Mtb QcrB.

Conclusions:

• 3-Aryl-substituted imidazo[1,2-a]pyridines represent a promising class of compounds for the development of new antituberculosis drugs.
• Compound 26 is a valuable lead candidate for further optimization and development as a novel anti-TB therapeutic.